Plain-English translation of NCT04697095 on ClinicalTrials.gov ↗ ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are trying to understand why people with atrophic age-related macular degeneration (a slowly progressing form of vision loss) have an accumulation of immune cells called monocytes in their eyes. This study will compare blood samples from people with different types of macular degeneration and healthy volunteers to see if monocytes from AMD patients behave differently. The goal is to identify new treatment targets for this currently untreatable form of blindness.
Currently, there are no treatments available for atrophic macular degeneration, the slow-progressing form that causes irreversible blindness. By understanding how immune cells contribute to this disease, researchers hope to develop targeted therapies that could slow or stop vision loss.
You likely qualify if…
You likely don't qualify if…
As a participant, you would donate a blood sample during a visit, similar to a routine blood test. Researchers will then examine your monocytes in the laboratory to compare how they function compared to samples from other participants. The study is observational, meaning you will not receive any experimental treatment — you are simply helping researchers gather information about how immune cells differ among people with various stages of macular degeneration.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France